Show simple item record

dc.contributor.authorGalli, Flavia
dc.contributor.authorBindo, Francesco
dc.contributor.authorMotos, Anna
dc.contributor.authorFernández Barat, Laia
dc.contributor.authorBarbeta, Enric
dc.contributor.authorEstella García, Ángel 
dc.contributor.otherMedicinaes_ES
dc.date.accessioned2024-05-22T09:23:23Z
dc.date.available2024-05-22T09:23:23Z
dc.date.issued2023
dc.identifier.issn1432-1238
dc.identifier.issn0342-4642
dc.identifier.urihttp://hdl.handle.net/10498/32329
dc.description.abstractAlthough the prevalence of community-acquired respiratory bacterial coinfection upon hospital admission in patients with coronavirus disease 2019 (COVID-19) has been reported to be < 5%, almost three-quarters of patients received antibiotics. We aim to investigate whether procalcitonin (PCT) or C-reactive protein (CRP) upon admission could be helpful biomarkers to identify bacterial coinfection among patients with COVID-19 pneumonia. Methods: We carried out a multicentre, observational cohort study including consecutive COVID-19 patients admitted to 55 Spanish intensive care units (ICUs). The primary outcome was to explore whether PCT or CRP serum levels upon hospital admission could predict bacterial coinfection among patients with COVID-19 pneumonia. The secondary outcome was the evaluation of their association with mortality. We also conducted subgroups analyses in higher risk profile populations. Results: Between 5 February 2020 and 21 December 2021, 4076 patients were included, 133 (3%) of whom presented bacterial coinfection. PCT and CRP had low area under curve (AUC) scores at the receiver operating characteristic (ROC) curve analysis [0.57 (95% confidence interval (CI) 0.51–0.61) and 0.6 (95% CI, 0.55–0.64), respectively], but high negative predictive values (NPV) [97.5% (95% CI 96.5–98.5) and 98.2% (95% CI 97.5–98.9) for PCT and CRP, respectively]. CRP alone was associated with bacterial coinfection (OR 2, 95% CI 1.25–3.19; p = 0.004). The overall 15, 30 and 90 days mortality had a higher trend in the bacterial coinfection group, but without significant difference. PCT ≥ 0.12 ng/mL was associated with higher 90 days mortality. Conclusion: Our study suggests that measurements of PCT and CRP, alone and at a single time point, are not useful for ruling in or out bacterial coinfection in viral pneumonia by COVID-19.es_ES
dc.formatapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherSpringeres_ES
dc.rightsAtribución-NoComercial 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.sourceIntensive Care Medicine, Vol. 49, Núm. 8, 2023, pp. 934-945es_ES
dc.subjectBacterial coinfectiones_ES
dc.subjectC-reactive proteines_ES
dc.subjectCOVID-19es_ES
dc.subjectCritically illes_ES
dc.subjectIntensive carees_ES
dc.subjectProcalcitonines_ES
dc.titleProcalcitonin and C-reactive protein to rule out early bacterial coinfection in COVID-19 critically ill patientses_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.1007/S00134-023-07161-1
dc.relation.projectIDCD21/00087es_ES
dc.type.hasVersionVoRes_ES


Files in this item

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial 4.0 Internacional
This work is under a Creative Commons License Atribución-NoComercial 4.0 Internacional